COVID19 Vaccination in Frail People. Lots of Hope and Some Questions

Rolland, Yves; Cesari, Matteo; Morley, John E.; Merchant, Reshma Aziz; Vellas, Bruno

doi:10.1007/s12603-021-1591-9

Cited by 13 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, some people reside in nursing homes, which puts them at increased risk of acquiring communicable infections, such as Covid‐19. 161 Therefore, prevention of SARS‐CoV‐2 infection seems to be the most desirable approach in these patients. There is substantial concern that these people would not achieve favourable protective immunity post‐vaccination, considering this population's relatively weak antibody response.…”

Section: Elderlymentioning

confidence: 99%

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Afshar

Babazadeh

Janbakhsh

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

show abstract

Section: Elderlymentioning

confidence: 99%

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Afshar

Babazadeh

Janbakhsh

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…4 , 5 , 6 , 7 Nursing home residents are typically older, with higher levels of frailty and medical comorbidity and vaccinations are typically less efficacious in this group than in their community-dwelling counterparts. 8 , 9 , 10 Recent studies have supported the clinical efficacy of SARS-CoV-2 vaccination in older nursing home residents. 11 , 12 …”

mentioning

confidence: 99%

Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents

Dyer

Noonan

McElheron

et al. 2022

Journal of the American Medical Directors Association

View full text Add to dashboard Cite

Objectives Older nursing home residents make up the population at greatest risk of morbidity and mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. No studies have examined the determinants of long-term antibody responses post vaccination in this group. Design Longitudinal cohort study. Setting and Participants Residents from 5 nursing homes assessed before vaccination, and 5 weeks and 6 months post vaccination, with the BNT162b2 messenger RNA SARS-CoV-2 vaccine. Methods Comprehensive clinical assessment was performed, including assessment for comorbidity, frailty, and SARS-CoV-2 infection history. Serum nucleocapsid and anti-spike receptor binding domain (RBD) antibodies were analyzed at all timepoints. An in vitro angiotensin-converting enzyme (ACE2) receptor-spike RBD neutralization assay assessed serum neutralization capacity. Results Of 86 participants (81.1 ± 10.8 years; 65% female), just under half (45.4%; 39 of 86) had evidence of previous SARS-CoV-2 infection. All participants demonstrated a significant antibody response to vaccination at 5 weeks and a significant decline in this response by 6 months. SARS-CoV-2 infection history was the strongest predictor of antibody titer (log-transformed) at both 5 weeks [β: 3.00; 95% confidence interval (CI): 2.32–3.70; P < .001] and 6 months (β: 3.59; 95% CI: 2.89–4.28; P < .001). Independent of SARS-CoV-2 infection history, both age in years (β: −0.05; 95% CI: −0.08 to −0.02; P < .001) and frailty (β: −0.22; 95% CI: −0.33 to −0.11; P < .001) were associated with a significantly lower antibody titer at 6 months. Anti-spike antibody titers at both 5 weeks and 6 months significantly correlated with in vitro neutralization capacity. Conclusions and Implications In older nursing home residents, SARS-CoV-2 infection history was the strongest predictor of anti-spike antibody titers at 6 months, whereas age and frailty were independently associated with lower titers at 6 months. Antibody titers significantly correlated with in vitro neutralization capacity. Although older SARS-CoV-2 naïve nursing home residents may be particularly vulnerable to breakthrough SARS-CoV-2 infection, the relationship between antibody titers, SARS-CoV-2 infection, and clinical outcomes remains to be fully elucidated in this vulnerable population.

show abstract

“…Vaccination campaigns are quickly turning the table against COVID-19. Massive efforts were put in place by most countries to acquire and distribute millions of doses all over the world (Rolland et al, 2021). Ever since their announcement in November 2020, vaccines were largely covered, described and debated by news and social media, creating a deluge of information consumed by individuals (Puri et al, 2020, Stella et al, 2021b, Murphy et al, 2021.…”

Section: Introductionmentioning

confidence: 99%

Writing about COVID-19 vaccines: Emotional profiling unravels how mainstream and alternative press framed AstraZeneca, Pfizer and vaccination campaigns

Semeraro¹,

Vilella²,

Ruffo³

et al. 2022

Preprint

View full text Add to dashboard Cite

Ever since their announcement in November 2020, COVID-19 vaccines were largely debated by the press and social media. With most studies focusing on COVID-19 disinformation in social media, little attention has been paid to how mainstream news outlets framed COVID-19 narratives compared to alternative sources. To fill this gap, we use cognitive network science and natural language processing to reconstruct time-evolving semantic and emotional frames of 5745 news about COVID-19 vaccines. Our dataset covers 17 outlets over 8 months and includes Italian news articles that were massively re-shared on Facebook (5 mil. total shares) and Twitter (200k total shares). We found consistently high levels of trust/anticipation and less disgust in the way mainstream sources framed the general idea of "vaccine/vaccino". These emotions were crucially missing in the ways alternative sources framed COVID-19 vaccines. More differences were found within specific instances of vaccines. Alternative news included titles framing the AstraZeneca vaccine with strong levels of sadness, absent in mainstream titles. Mainstream news initially framed "Pfizer" along more negative associations with side effects (e.g. "allergy", "reaction", "fever") than "AstraZeneca". With the temporary suspension of the latter vaccine, on March 15th 2021, we identified a semantic/emotional shift: Even mainstream article titles framed "AstraZeneca" as semantically richer in negative associations with side effects, while "Pfizer" underwent a positive shift in valence, mostly related to its higher efficacy. Thrombosis entered the frame of vaccines together with fearful conceptual associations, while the word death underwent an emotional shift, steering towards fear in alternative titles and losing its hopeful connotation in mainstream titles, with the lack of anticipation. Our findings expose crucial aspects of the emotional narratives around COVID-19 vaccines adopted by the press, highlighting the need to understand how alternative and mainstream media report vaccination news.

show abstract

COVID19 Vaccination in Frail People. Lots of Hope and Some Questions

Cited by 13 publications

References 12 publications

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents

Writing about COVID-19 vaccines: Emotional profiling unravels how mainstream and alternative press framed AstraZeneca, Pfizer and vaccination campaigns

Contact Info

Product

Resources

About